W. Cromlish

发表

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

M. Percival, D. Riendeau, B. Kennedy, 1999, Bioorganic & medicinal chemistry letters.

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.

B. Kennedy, W. Cromlish, M. Gresser, 1999, Science.

A Natural Disruption of the Secretory Group II Phospholipase A2 Gene in Inbred Mouse Strains (*)

J. Mudgett, W. Cromlish, D. Rancourt, 1995, The Journal of Biological Chemistry.

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

Sébastien Gagné, Eric Langlois, Jean-François Truchon, 2014, Bioorganic & medicinal chemistry letters.

The identification of potent, selective, and bioavailable cathepsin S inhibitors.

M. Percival, W. Cromlish, J. Gauthier, 2007, Bioorganic & medicinal chemistry letters.

An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells.

J. Falgueyret, S. Venkatraman, M. Percival, 2004, Analytical biochemistry.

NOVEL 1,2-DIARYLCYCLOBUTENES : SELECTIVE AND ORALLY ACTIVE COX-2 INHIBITORS

D. Riendeau, C. Chan, W. Cromlish, 1996 .

Basal Activation of p70S6K Results in Adipose-specific Insulin Resistance in Protein-tyrosine Phosphatase 1B–/– Mice*

Kenny K. Wong, B. Kennedy, W. Cromlish, 2007, Journal of Biological Chemistry.

The development of potent non-peptidic PTP-1B inhibitors.

E. Asante-Appiah, Y. Boie, B. Kennedy, 2004, Bioorganic & medicinal chemistry letters.

Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells

D. Riendeau, B. Kennedy, S. Charleson, 1997, Inflammation Research.

Prolactin (PRL) receptor induction in cultured rat hepatocytes: dual regulation by PRL and growth hormone.

W. Cromlish, B. Posner, I. Barash, 1988, Endocrinology.

Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors

M. Percival, D. Riendeau, W. Cromlish, 2011, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Selective inhibitors of COX-2.

J. Falgueyret, B. Kennedy, C. Chan, 1995, Agents and actions. Supplements.

Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma.

Christopher M. Tan, D. Slipetz, Sarah L. Huszar, 2011, American journal of respiratory cell and molecular biology.

Human cytosolic phospholipase A2 expressed in insect cells is extensively phosphorylated on Ser-505.

B. Kennedy, W. Cromlish, P. Payette, 1995, Biochimica et biophysica acta.

Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors

D. Riendeau, P. Prasit, C. Brideau, 1997 .

Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA.

B. Kennedy, W. Cromlish, C. Chan, 1993, Biochemical and biophysical research communications.

High-level expression of active human cyclooxygenase-2 in insect cells.

M. Percival, B. Kennedy, W. Cromlish, 1994, Archives of biochemistry and biophysics.

Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors.

C. Bayly, E. Asante-Appiah, Y. Boie, 2004, Bioorganic & medicinal chemistry letters.

Development and validation of an intact cell assay for protein tyrosine phosphatases using recombinant baculoviruses.

B. Kennedy, W. Cromlish, P. Payette, 1999, Biochemical pharmacology.

A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 1999, Bioorganic & medicinal chemistry letters.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

J. Falgueyret, J. Palmer, M. Venuti, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 2,3-diarylthiophenes as selective cox-2 inhibitors. part II: Replacing the heterocycle

D. Riendeau, P. Prasit, W. Cromlish, 1996 .

A new series of selective COX-2 inhibitors : 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

P. Prasit, C. Brideau, C. Chan, 1997 .

The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.

C. Bayly, C. Desponts, E. Asante-Appiah, 2003, Biochemistry.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

J. Falgueyret, M. Percival, D. Riendeau, 1997, British journal of pharmacology.

Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.

D. Riendeau, S. Charleson, W. Cromlish, 1997, Canadian journal of physiology and pharmacology.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

H Perrier, R Gordon, M. Percival, 1999, The Journal of pharmacology and experimental therapeutics.

Transcriptionally active immediate-early protein of pseudorabies virus binds to specific sites on class II gene promoters

J. Workman, M. Horikoshi, R. Roeder, 1989, Journal of virology.

Transcriptional regulation by the immediate early protein of pseudorabies virus during in vitro nucleosome assembly

J. Workman, R. Roeder, W. Cromlish, 1988, Cell.

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.

J. Falgueyret, M. Percival, R. Oballa, 2005, Journal of medicinal chemistry.

PTP1B-dependent insulin receptor phosphorylation/residency in the endocytic recycling compartment of CHO-IR cells.

B. Kennedy, W. Cromlish, Robert Kyskan, 2006, Biochemical pharmacology.

heart failure and cachexia Cardiac gene expression profile in rats with terminal

M. Lalowski, M. Orešič, M. Baumann, 2015 .

Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid.

J. Falgueyret, B. Kennedy, W. Cromlish, 1994, Molecular pharmacology.

Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2.

B. Kennedy, W. Cromlish, P. Payette, 1996, Biochemistry.

Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells.

Jilly F. Evans, J. Falgueyret, D. Riendeau, 1996, Biochemical pharmacology.

3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

D. Riendeau, P. Prasit, C. Brideau, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 Inhibitors. Part 2. Replacing the Heterocycle

D. Riendeau, P. Prasit, W. Cromlish, 1996 .

Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays.

B. Kennedy, W. Cromlish, 1996, Biochemical pharmacology.

A New Series of Selective COX-2 Inhibitors: 5,6-Diarylthiazolo(3,2-b)( 1,2,4)triazoles.

P. Prasit, C. Brideau, C. Chan, 1997 .

Pharmacological and genetic evidence that cathepsin B is not the physiological activator of rodent prorenin

M. Percival, W. Cromlish, J. Gauthier, 2010, Biological chemistry.

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 1999, Bioorganic & medicinal chemistry letters.

Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma.

Christopher M. Tan, D. Slipetz, Sarah L. Huszar, 2011, American journal of respiratory cell and molecular biology.

Novel 1,2‐Diarylcyclobutenes: Selective and Orally Active COX‐2 Inhibitors.

D. Riendeau, W. Cromlish, R. Gordon, 1997 .

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

J. Falgueyret, M. Percival, R. Oballa, 2010, Bioorganic & medicinal chemistry letters.